---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-008039"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:00:35.761766+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022

## Summary
- Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.
- Cash $551.8M (Dec 31, 2021) vs $177.0M; expects funding into at least 2024.
- XEN1101 Phase 2b met primary endpoint; end-of-Phase 2 FDA meeting Q2 2022; Phase 3 start H2 2022.
- XEN496 Phase 3 EPIK trial for KCNQ2-DEE enrolling; completion expected H1 2023.
- Partner Neurocrine Phase 2 for NBI-921352 ongoing; Pacira Phase 1b for PCRX301 data expected Q2 2022.

## SEC filing metadata
- accession: 0001564590-22-008039
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022008039/0001564590-22-008039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022008039/xene-8k_20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-008039
- JSON: https://secwatch.observer/filing/0001564590-22-008039.json
- Plain text: https://secwatch.observer/filing/0001564590-22-008039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.